Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Haematologica
Prif Awduron: Castagnetti, Fausto, Breccia, Massimo, Gugliotta, Gabriele, Martino, Bruno, D’Adda, Mariella, Stagno, Fabio, Carella, Angelo Michele, Avanzini, Paolo, Tiribelli, Mario, Trabacchi, Elena, Visani, Giuseppe, Gobbi, Marco, Salvucci, Marzia, Levato, Luciano, Binotto, Gianni, Capalbo, Silvana Franca, Bochicchio, Maria Teresa, Soverini, Simona, Cavo, Michele, Martinelli, Giovanni, Alimena, Giuliana, Pane, Fabrizio, Saglio, Giuseppe, Rosti, Gianantonio, Baccarani, Michele
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ferrata Storti Foundation 2016
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5046649/
https://ncbi.nlm.nih.gov/pubmed/27470600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.144949
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg